Compare Estee Lauder Companies Inc (EL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs TransMedics Group Inc — how do they compare? Estee Lauder Companies Inc trades at $87.72 (market cap $31.76B), while TransMedics Group Inc trades at $87.69 (market cap $3.10B). The key difference: Estee Lauder Companies Inc is far larger — about 10.2× TransMedics Group Inc's market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| EL | TMDX | |
|---|---|---|
Market Cap | $31.76B | $3.10B |
Sector | Consumer Staples | Technology |
52-Week High | $119.61 | $150.42 |
52-Week Low | $67.23 | $61.99 |
Enterprise Value | $37.93B | $3.49B |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EL trades at $88.56, up 1.57% today, with a bullish technical trend and strong recent earnings beats. The stock shows robust gross margins of 74.71% but faces profitability challenges with a negative net income margin. Analyst consensus is mixed with a $91.67 price target, while recent news highlights new product launches and institutional accumulation.
Outlook remains cautiously optimistic given earnings momentum and brand strength, but high valuation multiples and inconsistent cash flow pose risks. Investors should weigh growth potential against margin pressures and macroeconomic sensitivity in the beauty sector.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
